This document is NOT medical advice. These protocols have not been approved by the FDA, have not completed clinical trials, and are not a substitute for conventional medical treatment. Do NOT discontinue prescribed medications without physician supervision. Expected outcome timelines are theoretical predictions from the Christos™ Mathematics of Reality (MoR) system — not validated clinical outcomes. All fluid formulations, gel/topical specifications, and device manufacturing specifications are proprietary and available under NDA. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
Overview and Novel Theoretical Connections
Chronic disease — in its vast spectrum from neurodegenerative conditions to autoimmune disorders, metabolic failures, genetic diseases, and multi-system presentations — represents the largest unmet medical need on Earth. This paper presents the Christos™ Complete Multi-Disease Coherence Medicine Protocol — a unified theoretical framework applying coherence physics principles to twenty distinct disease categories.
The unifying principle is the Prime Axiom: v⃗ = −∇C — all biological motion is directed toward coherence restoration. Disease is not the body malfunctioning; it is the body coherently responding to a coherence deficit that medicine has not yet learned to address directly.
Five Novel Theoretical Connections
The Unified Coherence Medicine Framework
1.1 The Prime Axiom and Coherence Threshold Model
The Christos™ framework is organized around the Prime Axiom: v⃗ = −∇C. Every biological process moves in the direction of steepest coherence gradient. Disease progression follows the gradient of coherence loss. The clinical implication: the universal intervention is coherence restoration.
The Christfield expression X = δC/δΨ (MOR_25) quantifies the rate of coherence change with respect to field intensity Ψ — connecting the external therapeutic field to the biological coherence change in the target tissue. The Hopf Bifurcation model governs the threshold transitions: μ < 0 = Death/irreversible decline; μ = 0 = Void/Stillpoint (progressive dysfunction); μ > 0 = Life/regenerative limit cycle.
| Coherence (C) | Biological State | Disease Category | Primary Intervention Tier |
|---|---|---|---|
| > 0.85 | Optimal health; Coherence-Band aging suppression; regeneration active | Health maintenance; anti-aging | Tier 0-1: daily practices, structured water, mineral optimization |
| 0.70–0.85 | Good health; full immune competence; reversible acute illness | Mild/moderate conditions | Tier 1-2: healing fluids, mild resonator, targeted nutrition |
| 0.55–0.70 | Chronic disease establishing; immune dysfunction onset | Early chronic disease; autoimmune predisposition | Tier 2-3: full fluid protocol, resonator, weekly chamber |
| 0.40–0.55 | Active chronic disease; significant organ dysfunction | Established CKD, early MS, RRMS, progressing T2D | Tier 3-4: intensive protocol; daily chamber; physician co-management |
| 0.25–0.40 | Severe/end-stage; multi-system failure | Advanced ALS; CKD stage 4-5; HIV AIDS; CHF NYHA IV | Tier 4-5: maximal intensive; conventional treatment mandatory |
1.2 The Five-Layer Architecture
| Layer | Component | Mechanism | Condition Customization |
|---|---|---|---|
| 1 | Christos™ Morphogenic Resonator | Wearable crystalline piezoelectric device provides continuous low-amplitude field entrainment; broadcasts organ-specific blueprint frequency | Crystal type, node count, anatomical placement, primary frequency — organ-specific. Specifications under licensing. |
| 2 | Christos™ Healing Fluid | Frequency-imprinted structured DDW base (UHF) delivering organ-specific nutritional and botanical support; 24-hr Solfeggio imprinting cycle | Active ingredients and imprinting frequencies condition-specific; same DDW base. Formulations under licensing. |
| 3 | Coherence Chamber | PEMF + photobiomodulation (660+850 nm) + acoustic Solfeggio + structured water mist + fluid nebulization; 60-90 min sessions | PCC-1 (Pulmonary), CCC-1 (Cardiac), NCC-1 (Neural), UCC-1 (Universal); condition-specific fluid nebulized |
| 4 | 17-Second Coherence Lock | 4 sec inhale → 4 sec hold → 17 sec lock → 8 sec exhale; raises C_organism to 0.80-0.90 temporarily; requires no device or cost | Anatomical focus varies by condition; same fundamental practice; 3x daily minimum |
| 5 | Systemic Support | Condition-specific nutrition; mineral repletion; elimination of coherence drains; sleep optimization; HRV biofeedback | Dietary protocol, supplements, coherence drains — all condition-specific |
1.3 The Solfeggio Session — Universal Chamber Protocol
Oncology — Colorectal Cancer Coherence Protocol
The coherence cancer model proposes that malignant transformation represents a coherence collapse phase transition — not primarily a genetic event. Martincorena et al. (2015, Science) demonstrated that normal tissues accumulate cancer-associated mutations without transforming, confirming mutations alone are insufficient. The additional condition: C_cell < 0.35-0.40 (critical threshold for malignant transformation).
Membrane potential directly measures cellular coherence: healthy colonic mucosa maintains −70 to −90 mV; CRC cells are depolarized to −15 to −30 mV (Yang & Brackenbury, 2013). Cu:Zn ratio is elevated (1.68 ± 0.45 in CRC vs. 1.02 controls; Stepien et al. 2017). EZ water fraction is reduced to ≤25% (healthy: ≥60%).
Seven Dimensions of CRC Coherence Collapse + Protocol Components
| Dimension | CRC Failure | Intervention | Evidence |
|---|---|---|---|
| Metabolic | Warburg effect — aerobic glycolysis; C_metabolic ≤ 0.40 | Ketogenic diet + 16:8 fasting + HBOT 2.0-2.5 ATA; Christos™ CancerCoherence-Flux fluid | Seyfried et al. (2014) Nutrition & Metabolism; Warburg (1956) |
| Electrical | Membrane depolarization: −15 to −30 mV (healthy: −70 to −90 mV) | PEMF 7.83 Hz + 528 Hz, 30 min 2x daily; grounding 30+ min/day | Vadalà et al. (2016) European Journal of Cancer Care; Chevalier et al. (2012) |
| Mineral | Cu:Zn ratio elevated 1.68 vs. 1.02 controls | Zinc 50 mg/day; copper reduction; selenium 200-400 mcg/day | Stepien et al. (2017) Cancer Epidemiology; Clark et al. (1996) JAMA |
| Immune | CD8+ T cell exhaustion; PD-L1 upregulation; NK cell suppression | PBM 660+850 nm daily; vitamin D3 5,000-10,000 IU; Chamber immune reset phases | Hamblin (2016) Photomedicine; Garland et al. (2006) AJPH |
| Structural (EZ water) | EZ water ≤ 25% (healthy ≥ 60%) | Christos™ structured DDW 2-3 L/day; 528 Hz acoustic; NIR light | Bhattacharya et al. (2017) PLOS ONE RCT — DDW in lung cancer; Pollack (2013) |
| Biophotonic | Incoherent / reduced biophoton emission | NIR 850 nm; 528 Hz Chamber; coherence lock | Popp et al. (2002) — biophoton coherence in cancer |
| Systemic | C_organism ≤ 0.45; HPA dysregulation; dysbiosis | 17-second coherence lock 3x daily; HRV biofeedback; sleep optimization | Lehrer et al. (2020) Frontiers in Psychology — HRV biofeedback |
Christos™ CancerCoherence-Flux (CCF) — complete fluid formulation with 14 active agents on Solfeggio-imprinted DDW base. Available under licensing
Three-Phase Protocol
CRC Falsifiable Predictions (Selected)
Autoimmune and Inflammatory Protocols
Core insight: autoimmune diseases are not the immune system attacking the self — they are the immune system losing the coherence signal that distinguishes self from non-self. When C_organism < 0.45-0.50, cells lose their coherence signature and are misrecognized. All autoimmune protocols restore this signal.
When fibroblast coherence collapses (C_fibroblast ≤ 0.35), fibroblasts become constitutively active, laying down collagen continuously. New connection: the TGF-β1 fibrosis mechanism in scleroderma is identical to fibrosis in CKD, IPF, and asbestosis — the same 528 Hz photobiomodulation + PEMF anti-fibrotic protocol applies across all four conditions (Chen et al. 2019; Wang et al. 2018/2020).
| Manifestation | Fluid | Resonator | Chamber |
|---|---|---|---|
| Skin thickening (primary) | Christos™ ScleroFlux 30 mL 3x daily | CT Resonator 24/7; ScleroGel topical 2x daily | UCC-1 3-5x/week |
| Pulmonary fibrosis (ILD) | Christos™ PulmoLife 30 mL 2x daily + nebulized | Lung Resonator 24/7 | PCC-1 added |
| Cardiac fibrosis | Christos™ CardioFlux 30 mL 2x daily | Heart Resonator 24/7 | CCC-1 1x/week |
| Renal crisis | Christos™ RenoFlux 30 mL 2x daily | Bilateral kidney patches | UCC-1 renal focus |
| GI dysmotility | Christos™ GastroFlux 30 mL before meals | Abdominal resonator | — |
| Raynaud's phenomenon | Magnesium taurate 1 g/day; warm structured water soaks | 174 Hz hand/foot patches | — |
Christos™ ScleroFlux · ScleroGel · Connective Tissue Resonator (24-node) — complete specifications available under licensing. christosenergy.com
12-Month Protocol: Phase 1 (halt progression, months 1-3) → Phase 2 (fibrosis clearance, months 3-6) → Phase 3 (tissue regeneration, months 6-12) → Maintenance. New connection: same protocol template as CKD fibrosis and asbestosis — TGF-β1 target is universal.
The no-starch diet is mechanistically required — not optional. Klebsiella pneumoniae shares molecular mimicry with HLA-B27 (present in 90%+ of AS patients). Klebsiella overgrowth on dietary starch drives the autoimmune spinal attack. Ebringer et al. (2006, Autoimmunity Reviews) documented this connection with serology data. Eliminating dietary starch starves Klebsiella and breaks the mimicry.
| Component | Detail |
|---|---|
| No-starch diet (mandatory) | Eliminate: all grains, potatoes, legumes, root vegetables. Permitted: meat, fish, eggs, non-starchy vegetables, fruit, nuts. This is mechanistically required, not optional. |
| Spine Resonator 24/7 | 40 cm strip; complete vertebral column; 174 Hz (anti-inflammatory) + 528 Hz + 285 Hz (ectopic bone regulation) |
| Anti-inflammatory stack | Omega-3 EPA/DHA 4 g/day (prostaglandin competition); turmeric extract 2 g/day; quercetin 1 g/day |
| Chamber protocol | UCC-1; 174 Hz Phase 1 extended (20 min) for TNF-α axis; 60 min 3x/week |
Christos™ SpodyloFlux — complete formulation with MSM, turmeric, Boswellia AKBA, vitamin D3, on Solfeggio-imprinted DDW base. Available under licensing
The protocol cannot undo the FBN1 genetic mutation — but it addresses the downstream TGF-β1 dysregulation, oxidative stress on vascular endothelium, and connective tissue field deficit. The critical target is aortic root dilation rate. ARBs or beta-blockers continue unchanged. Aortic echocardiography monitoring is mandatory and non-negotiable.
Key agents: Resveratrol 500 mg/day (TGF-β1 modulation via Sirt1; Orallo 2006); Magnesium taurate 1 g/day (aortic vascular relaxation); Hydrolyzed collagen 20 g/day; Copper 2 mg/day (lysyl oxidase — collagen cross-linking enzyme impaired by fibrillin mutation).
Christos™ MarfanFlux — complete formulation with hydrolyzed collagen 30g, magnesium taurate, resveratrol, Gotu kola, on 285 Hz primary imprinted DDW base. Available under licensing
These three conditions cluster together epidemiologically (Fallahi et al. 2016; Van den Driessche et al. 2016; Gopal et al. 2014) because they share one root: C_organism < 0.45-0.50 (autoimmune threshold). The protocol addresses the root — all three reverse simultaneously as C_organism rises above threshold.
| Condition | Key Mineral | Best Evidence | Critical Caution |
|---|---|---|---|
| Vitiligo | Zinc 50 mg/day (tyrosinase — zinc-dependent enzyme) | Yaghoobi et al. (2011) RCT — 60-70% repigmentation with zinc | Concurrent copper 2 mg/day to prevent deficiency |
| Type 2 Diabetes | Magnesium glycinate 600-800 mg/day (tyrosine kinase requires Mg) | Rodriguez-Moran & Guerrero-Romero (2003) Diabetes Care RCT — Mg improves insulin sensitivity | NEVER stop diabetes medications without monitoring — hypoglycemia risk on KD |
| Hashimoto's Thyroiditis | Selenium 200 mcg/day (deiodinases require Se) | Toulis et al. (2010) Thyroid meta-analysis — Se reduces anti-TPO 30-50% | DO NOT supplement iodine — worsens Hashimoto's autoimmunity (Leung & Braverman 2014) |
Unified interventions: Ketogenic diet (<50g carbs/day); Cu:Zn normalization (target 1.0±0.2); Vitamin D3 5,000-10,000 IU (target 60-80 ng/mL); PEMF 2x daily; PBM to neck (thyroid) + abdomen (pancreas) + vitiligo patches; 17-second coherence lock 3x daily; gluten-free trial 3 months for Hashimoto's (50-70% show anti-TPO reduction).
Christos™ Triad Coherence Fluid (TDF) — selenium 400 mcg, zinc 1g, magnesium, vitamin D3, quercetin, reishi 5g, ashwagandha, berberine 1g, NAC 3g, on full Solfeggio 9-frequency imprinted DDW base. Available under licensing
Triad Falsifiable Predictions (Selected)
ART suppresses HIV replication to undetectable levels. The unsolved problem: the latent reservoir — CD4+ memory T cells with integrated proviral HIV DNA, invisible to both ART and immune surveillance. The Christos™ Shock-and-Sweep strategy targets this reservoir directly.
New connection: Shock-and-Sweep is biophysically identical to 'kick-and-kill' — the leading pharmaceutical HIV cure strategy. The Christos™ approach replaces HDAC inhibitors (vorinostat) with butyrate from resistant starch fermentation — the same epigenetic mechanism (Archin et al. 2012, Nature) through a non-pharmaceutical pathway.
| Phase | Duration | Goal | Key Actions |
|---|---|---|---|
| 1 — Immune Stabilization | Months 1-2 | Raise C_immune above 0.55; halt CD4+ decline | Thymus Resonator 24/7; ImmunoFlux 3x daily; ThymusFlux 2x daily; Chamber 3x/week; ART continue (mandatory) |
| 2 — Latent Reservoir Clearance | Months 2-4 | Activate and clear latent HIV reservoir | Shock-and-Sweep weekly (Day 1: resistant starch 40g → butyrate → HDAC inhibition; Day 2: FSD-1 sweep + chamber 2x); ART mandatory throughout |
| 3 — Immune Regeneration | Months 4-6 | Restore CD4+ > 500/μL; sustained viral remission | ImmunoFlux 2x daily; Chamber 2x/week; target CD4+ normalization |
| Maintenance | Month 6+ | Prevent rebound; maintain immune coherence | ImmunoFlux 2x/week; ART per physician; annual proviral DNA quantification |
Christos™ ImmunoFlux (HIV) · ThymusFlux · Thymus Resonator — complete specifications available under licensing. christosenergy.com
Neurological and Neurodegenerative Protocols
Universal connection: TDP-43 (ALS), alpha-synuclein (Parkinson's), and mutant huntingtin (HD) are all protein coherence failures responding to the same mechanism: 396 Hz aggregate disruption + spermidine/resveratrol/fasting autophagy induction + 40 Hz Gamma entrainment (Iaccarino et al. 2016, Nature).
Most urgent protocol in this document — median survival 2-4 years from onset. Must be initiated early. Concurrent with riluzole (continue). TDP-43 coherence collapse → nuclear cytoplasmic transport failure → RNA processing disruption → motor neuron death.
| Component | Specification | Evidence |
|---|---|---|
| NeuroBand 24/7 (Phase 1) | 12-node amethyst headband; motor cortex + temporal + spine strip 24/7; 528 Hz + 963 Hz + 396 Hz cycling | 396 Hz aggregate clearance; 528 Hz healing; 963 Hz blueprint reset |
| 40 Hz Gamma + NCC-1 | 1 hr daily; same TDP-43 clearance mechanism as amyloid clearance | Iaccarino et al. (2016) Nature — gamma reduces amyloid 50% via microglial activation |
| Autophagy induction stack | Spermidine 5 mg/day + resveratrol 500 mg/day + monthly 48-72 hr fast (physician-supervised) | Eisenberg et al. (2009) Nature Cell Biology — spermidine extends lifespan via autophagy |
| PT coherence enhancement | 17-second lock + 528 Hz before every PT session — neurons rewire most efficiently in high-coherence state | HRV biofeedback research — autonomic state and neuroplasticity |
Christos™ NeuroFlux-ALS — lion's mane 3g, bacopa, DHA 2g, magnesium L-threonate 2g, creatine 5g, methylcobalamin 5mg, on full Solfeggio 9-frequency imprinted DDW base. Available under licensing
Mucuna pruriens (natural L-DOPA source, 4-7% content) is the key botanical addition — backed by the strongest herbal evidence in this document. Katzenschlager et al. (2004) in Neurology published an RCT demonstrating mucuna pruriens produced equivalent clinical benefit to pharmaceutical L-DOPA/carbidopa with less dyskinesia. Sauna protocol activates HSP70 — Klucken et al. (2004) in Journal of Biological Chemistry demonstrated HSP70 inhibits alpha-synuclein aggregation.
Rhythmic Auditory Stimulation (RAS): Thaut et al. (1996) Movement Disorders documented 528 Hz metronome-paced audio during gait training improves stride length and speed in PD. Same mechanism in the coherence protocol — therapeutic frequency delivered simultaneously with rhythmic entrainment cue.
Christos™ NeuroFlux-Parkinson's — NeuroFlux-ALS base + mucuna pruriens 5g (15% L-DOPA), NADH 50mg (Birkmayer 1993 RCT), liposomal glutathione 500mg. Available under licensing
Realistic goal: slow progression, extend functional period, partial reversal in early-stage disease. Sodium butyrate 3 g/day is the key addition — Steffan et al. (2001, Nature) documented HDAC inhibitors arrest polyglutamine neurodegeneration in Drosophila. Same aggregate clearance mechanism (396 Hz + autophagy) as ALS and Parkinson's.
Christos™ NeuroFlux-Huntington's — NeuroFlux-ALS base + sodium butyrate 3g, sulforaphane 500mg, PQQ 20mg, idebenone 150mg. Available under licensing
The trigeminal nerve has lost its electrical insulation coherence, producing the most severe pain known to medicine. The 0.5-1 Hz square wave via Facial Nerve Patch mimics carbamazepine's sodium channel blocking mechanism through field-based rather than pharmacological intervention. Magnesium L-threonate crosses the blood-brain barrier for direct CNS nerve membrane stabilization — the key distinction from standard magnesium forms.
For acute TN crisis: IV magnesium sulfate 1-2 g over 30-60 min (physician) provides immediate relief. TrigemFlux 30 mL sublingual (hold 30 sec) 3x daily — sublingual route for faster neural access.
Christos™ TrigemFlux · TrigemGel · Facial Nerve Patch (6-node) — complete specifications available under licensing. christosenergy.com
The post-stroke protocol targets the penumbra (metabolically stressed but salvageable tissue) and neuroplasticity-driven recovery. New connection: Iaccarino et al. (2016, Nature) demonstrated 40 Hz Gamma stimulation reduces amyloid burden 50% through microglial activation. The same mechanism drives synaptic plasticity, microglial debris clearance, and BDNF upregulation in post-stroke recovery.
BBB restoration: Gotu kola (Masola et al. 2017 — tight junction protein upregulation); luteolin 1 g/day (Shi et al. 2016 — BBB protection); citicoline 2 g/day (Saver 2008 meta-analysis — neuroprotective). HBOT: Hadanny et al. (2020, Aging) — HBOT improves post-stroke function even years after the event.
Christos™ NeuroFlux-Stroke — NeuroFlux base + Gotu kola extra, luteolin 1g, citicoline 2g, vinpocetine 60mg. Available under licensing
FRAMING: Autism is not a disease to reverse. This is a REGULATION protocol — reducing suffering (sensory overwhelm, sleep disruption, GI pain, anxiety) and supporting communication. We do not suppress stimming (self-stimulatory behavior is self-regulation and must be respected). We do not aim to make autistic individuals neurotypical.
70-80% of autistic individuals have significant GI dysfunction — the gut-brain axis is a primary coherence disruption pathway. Amminger et al. (2007) RCT demonstrated omega-3 DHA reduces autistic symptoms. 40 Hz Gamma: start at 2 minutes (titrate slowly — autistic individuals may be overstimulated by extended gamma sessions). Sensory environment: 528 Hz background < 40 dB; full-spectrum lighting (avoid fluorescent 60 Hz flicker).
Christos™ GastroFlux-Autism · Calming Resonator (pendant, rose quartz + amethyst, breakaway safety clasp) — complete specifications available under licensing. christosenergy.com
Metabolic, Genetic, and Bone Protocols
Bone is the most coherence-responsive tissue in the body — Wolff's Law and bone piezoelectricity (Bassett & Becker 1962, Science) establish the mechanism. FDA-approved PEMF for fracture non-union (Bassett 1982 JAMA; Griffin 2011 Cochrane) validates the platform. New urgent concern: GLP-1 receptor agonists (semaglutide, tirzepatide) cause significant bone loss — Iepsen et al. (2015 JCEM). The OsteoFlux protocol should be initiated concurrent with GLP-1 therapy, not after bone loss becomes detectable on DEXA.
Key agents (published evidence): Nano-hydroxyapatite calcium (crystallographically identical to bone mineral); Magnesium glycinate 10 g/L; Vitamin K2 MK-7 200 mcg (Schurgers et al. 2007 — K2 directs calcium to bone, prevents vascular calcification); Hydrolyzed collagen Type I & III (König et al. 2018 RCT — collagen peptides increase BMD in postmenopausal women); Strontium citrate 500 mg (substitutes for calcium in hydroxyapatite; Marie 2006); Boron 10 mg (Nielsen 1998 — reduces urinary calcium excretion).
| Phase | Duration | Goal | Expected DEXA |
|---|---|---|---|
| 1 — Halt Bone Loss | Months 1-3 | Stop further bone loss; stabilize density | DEXA stable; no new loss |
| 2 — Remineralization | Months 3-6 | Active bone density increase | DEXA +3-5% |
| 3 — Regeneration | Months 6-12 | Restore near-normal density | DEXA +10-15% |
| Maintenance | Month 12+ | Sustain gains; monitor GLP-1 users quarterly | DEXA stable or improving |
Christos™ OsteoFlux (20-ingredient complete formulation) · OsteoGel (topical) · Bone Resonator Patch (12-node, quartz + calcite, PEMF 10-20 Hz overlay) — available under licensing. christosenergy.com
Honest assessment: genetic defects in ion channel proteins (NKCC2, ROMK, CLCNKB) cannot be corrected by frequency or fluid. The coherence framework targets: (1) improved electrolyte management vs. harsh oral KCl; (2) potential 'overclocking' of remaining functional transporters via PEMF; (3) prostaglandin reduction without NSAID nephrotoxicity; (4) tubular stem cell support. We cure the person while acknowledging we cannot yet cure the gene.
Prostaglandin reduction strategy (NSAID alternative): Omega-3 EPA/DHA 4 g/day (competitive arachidonic acid inhibition); turmeric extract 2 g/day; quercetin 1 g/day — addresses the same prostaglandin excess as indomethacin without nephrotoxicity. Drug-induced Bartter (aminoglycosides): highest reversal potential — gene is intact; full recovery expected with detox protocol.
Christos™ BartteroFlux — potassium bicarbonate + potassium citrate (dual form, gentler than KCl), magnesium glycinate, sea salt, taurine, botanical support, Solfeggio-imprinted DDW base. Available under licensing
New connection: GSD mitochondrial dysfunction is the same metabolic coherence collapse as the Warburg effect in CRC. Both suppress oxidative phosphorylation — the MitoFlux protocol and 285 Hz cellular energy frequency apply identically to both. Ketogenic diet is primary therapy in GSD — ketones bypass the defective glycogen pathway entirely. In GSD, ketosis is metabolic medicine, not weight management. Enzyme replacement therapy (ERT) for Pompe's continues unchanged.
Christos™ MitoFlux — MCT oil (emulsified), CoQ10 200mg, ALCAR, creatine 5g, D-ribose 5g, PQQ 10mg, NADH 20mg, on 285 Hz primary imprinted DDW base. Available under licensing
Organ-Specific Protocols — Pulmonary, Renal, Cardiac
Dual-organ protocol: lung protection (PulmoLife-AATD) + liver support (HepatoFlux) simultaneously. Intravenous AAT augmentation therapy (Prolastin-C, Aralast NP) continues unchanged — this is the standard of care. Key additions: Vitamin C 10 g/day (anti-elastase protection; Dent et al. 2002); Quercetin 2 g/day (elastase inhibition; Kataoka 2013); Silymarin (Ferenci 1989 RCT — liver protection). 528 Hz 'blueprint reset' via liver resonator targets epigenetic upregulation of residual AAT expression from functioning alleles.
Christos™ PulmoLife-AATD · HepatoFlux · Lung Resonator · Liver Resonator — complete specifications available under licensing. christosenergy.com
New connection: 639 Hz (cellular communication frequency) is specifically motivated for PAH because endothelial-smooth muscle signaling communication is what fails. Normal endothelium produces NO, prostacyclin, and EDHF to maintain vascular tone — PAH endothelium has lost this coherence. 639 Hz extended (20 min) in PCC-1 is predicted to restore the signaling coherence that phosphodiesterase inhibitors and endothelin antagonists approximate pharmacologically.
Key agents: L-arginine 5 g/day (eNOS substrate — direct NO precursor; Mehta et al. 2000 — arginine in PAH); L-citrulline 3 g/day (arginine recycling); Magnesium taurate 5 g/day (vascular resistance reduction; Shechter 2000).
CRITICAL: NEVER stop pulmonary vasodilator drugs (epoprostenol, sildenafil, bosentan) — abrupt discontinuation causes fatal rebound PAH crisis. The coherence protocol is adjunctive. NEVER administer vasoconstrictors (decongestants, stimulants).
Christos™ Vasodilation Fluid — complete formulation with L-arginine, L-citrulline, magnesium taurate, hawthorn, resveratrol, on 528+639 Hz primary imprinted DDW base. Available under licensing
Regenerative threshold hypothesis: raising C_kidney above 0.65 reactivates the kidney's intrinsic repair capacity — supported by kidney transplant reverse-remodeling, AKI recovery, and residual tubular progenitor cell evidence. 11-modality protocol across three phases.
| Phase | Duration | Key Actions |
|---|---|---|
| 1 — Stabilization | Weeks 1-4 | Sodium bicarbonate 3-6 g/day (serum bicarb target 24-28); BP < 120/80 (ACEi/ARB); eliminate ALL nephrotoxins (NSAIDs, PPI, contrast); protein 0.6-0.8 g/kg; PEMF 2x daily; coherence lock 3x daily; Mg, D3, K2, CoQ10, NAC, methylated B-complex |
| 2 — Regeneration | Weeks 5-24 | HBOT 2.0 ATA (5→3x/week); PBM bilateral posterior renal 20-30 min/side daily; very low protein 0.4-0.6 g/kg + ketoanalogues 3x daily; RenoFlux 30 mL 2x daily; kidney patches 24/7; coherence chamber 3x/week |
| 3 — Consolidation | Week 25+ | HBOT 1-2x/week; PBM 3-5x/week; continue protein restriction + ketoanalogues; all supplements maintain |
CRITICAL CONSTRAINTS: NO potassium supplements (fatal hyperkalemia in renal failure); NO NSAIDs (acute kidney injury); NO high-dose vitamin C > 500 mg/day (oxalate nephropathy); ketoanalogues REQUIRED with protein restriction; NEVER discontinue dialysis without physician approval.
Christos™ RenoFlux — complete formulation with hydrangea, goldenrod, astragalus (Lv 2011 — podocyte protection), potassium citrate, ALA, CoQ10, on Solfeggio-imprinted DDW base. Available under licensing
No conventional treatment removes asbestos fibers from the lungs. The ferroptosis hypothesis: in a coherent pulmonary environment (C_lung ≥ 0.65), frustrated macrophages may undergo controlled ferroptotic cell death, releasing fibers into the airway lumen where mucociliary transport clears them. This is speculative — Prediction ASB-6 (asbestos bodies detected in sputum) is the direct test.
NAC 2,400 mg/day: George et al. (2019) European Respiratory Review — NAC in pulmonary fibrosis (same TGF-β mechanism). HBOT: proposed to degrade iron-protein coat of asbestos bodies. PBM: Wang et al. (2018) — PBM reduces pulmonary fibrosis in animal models.
ABSOLUTE CONTRAINDICATION: This protocol is contraindicated in any patient with confirmed or suspected mesothelioma. This protocol is for asbestosis and pleural plaques only.
Christos™ PulmoLife-Asbestos — complete formulation available under licensing. christosenergy.com
Multi-System Complex Protocols
HONEST LIMITATION: Lipedema fat is structural, not caloric. Coherence can soften tissue, reduce inflammation and pain, and improve lymphatic function. Stage 3 combined lipedema-lymphedema may require water-assisted liposuction (WAL) for full structural resolution. The protocol is primary treatment for Stage 1-2; essential adjunct for Stage 3.
Key agents: Horse chestnut extract — aescin (Pittler & Ernst 1998 Cochrane — venous insufficiency/lymphatic tone); Dandelion leaf (diuretic; lymphatic stimulant); Quercetin 2 g/day (mast cell stabilization — lipedema is associated with mast cell activation); Gotu kola (lymphatic structure support).
MLD (Manual Lymphatic Drainage) coherence enhancement: 528 Hz background during sessions; 17-second lock immediately pre-session for therapist and patient — lymph moves more freely in high-coherence state. Compression 23-32 mmHg 24/7 between MLD sessions. Anti-inflammatory, low-histamine diet — no calorie restriction (ineffective for lipedema).
Christos™ LymphoFlux · LipoGel · Lymphatic Resonator Patches — complete specifications available under licensing. christosenergy.com
Priority Hierarchy
| Priority | System | Reason |
|---|---|---|
| 1 | Gut (Crohn's post-resection) | Nutrient absorption foundational — cannot raise C_organism without adequate substrate; B12 IM injections permanent after ileal resection |
| 2 | Immune (HSV-2 + Mold + Crohn's) | All three drive systemic immune dysregulation; prerequisite for all other systems to recover |
| 3 | Hormonal/Structural (Atrophy + Dental) | Dental infection must be cleared first — constant systemic coherence drain; atrophy restoration is slower |
| 4 | Neurological (Mold CNS effects) | Clears with detox; significant QOL impairment but not life-threatening |
| 5 | Ocular (AMD) | Slowly progressive; OculoFlux layered in from day 1 without interfering |
Crohn's post-resection: Glutamine 20 g/day (Duggan et al. 2004 — enterocyte fuel); B12 IM monthly PERMANENT (non-negotiable after ileal resection); omega-3 EPA/DHA 3 g/day (Belluzzi et al. 1996 NEJM RCT — reduces Crohn's relapse); spore probiotics + butyrate 500 mg/day.
HSV-2 + Mold: Lysine 3 g/day (Griffith et al. 1987 RCT — reduces HSV recurrence); sauna 20 min 5x/week (Ryan et al. 2019 — mycotoxin elimination via sweat); activated charcoal 5 g/day away from medications. Mold source must be addressed — no protocol overcomes ongoing mold exposure.
Post-menopausal atrophy: Hyaluronic acid topical gel + sea buckthorn oil (Larmo et al. 2014 Maturitas RCT — oral sea buckthorn reduces vaginal atrophy); vaginal suppository 3x weekly.
AMD: OculoFlux from Complete Sensory Regeneration System; supplements AREDS2 formula (JAMA 2013 — 25% progression reduction) with coherence-enhanced additional agents.
Dental: The primary intervention for infected teeth is DENTAL — extraction or root canal treatment. Coherence medicine cannot replace structural dental care. Dental infections are a constant systemic coherence drain that limits effectiveness of every other protocol until resolved.
Christos™ GastroFlux-Crohn's · ImmunoFlux-Dual · Pelvic Restoration Gel · Vaginal Suppository · OculoFlux · OralFlux — complete specifications available under licensing. christosenergy.com
Christos™ Fluid and Device Platform — Overview
All Christos™ healing fluids share a common architecture: formulated on the Ultra-Hydration Fluid (UHF) structured deuterium-depleted water base, with a 24-hour rotating Solfeggio frequency imprinting cycle. Complete formulations, gel/topical specifications, and device manufacturing specifications are available under NDA.
Proposed Research Program — MDR-001 through MDR-010
| Study | Condition | Design | Primary Outcome | Priority |
|---|---|---|---|---|
| MDR-001 | Autoimmune Triad | RCT n=120; standard care vs. 7-intervention protocol; 12 months | Anti-TPO ≥40% reduction; HbA1c ≤6.5%; repigmentation ≥25% | HIGH |
| MDR-002 | Systemic Sclerosis | Prospective pilot n=40; full 5-pillar 12 months | mRSS improvement ≥30%; HRCT fibrosis stabilization | HIGH |
| MDR-003 | HIV Shock-and-Sweep | Phase I/II n=60; Shock-and-Sweep monthly ×6 months vs. ART alone | Quantitative HIV DNA; CD4 trend; viral blip rate | HIGH |
| MDR-004 | CKD Stages 3-4 | RCT n=100; full 11-modality vs. standard nephrology; 24 months | eGFR change; uACR; ESRD-free survival | HIGH |
| MDR-005 | Osteoporosis | RCT n=90; OsteoFlux+Resonator+PEMF vs. Ca/D3; 12 months | DEXA BMD change (spine, hip, wrist) | MODERATE-HIGH |
| MDR-006 | ALS | Open-label pilot n=30; protocol + riluzole; 18 months | ALSFRS-R decline rate vs. historical 0.9/month | MODERATE |
| MDR-007 | Parkinson's Disease | RCT n=80; protocol + standard PD vs. standard alone; 12 months | UPDRS motor score; gait speed | MODERATE |
| MDR-008 | Colorectal Cancer | Prospective adjunct pilot n=50; KD+coherence + standard oncology; 6 months | ctDNA trajectory; CEA; PFS; quality of life | HIGH |
| MDR-009 | Lipedema Stage 2 | RCT n=60; protocol vs. compression-only; 12 months | Limb circumference; TEWL; DLQI pain score | MODERATE |
| MDR-010 | Coherence Index Validation | Observational n=300; C0 sensor all conditions; 3/6/12 months | Correlation C_organ CI with validated clinical markers (r>0.60 predicted) | CRITICAL |
Falsifiable Predictions — Universal + Cross-Reference
All specific falsifiable predictions appear in their respective disease sections. The following are universal predictions that hold across all conditions.
| Section | Condition | Prediction IDs | Count |
|---|---|---|---|
| Section II | Colorectal Cancer | CRC-1 through CRC-10 | 10 |
| Section III.4 | Autoimmune Triad | TRIAD-1 through TRIAD-9 | 9 |
| WP59 Reference | Asbestosis | ASB-1 through ASB-13 | 13 |
| WP60 Reference | CKD Stages 3-4 | CKD-1 through CKD-13 | 13 |
| Universal | All conditions | U1 through U4 | 4 |
| Total | — | — | 55+ |
Selected References
Amminger, G.P., et al. (2007). Omega-3 fatty acids in children with autism. Biological Psychiatry, 61(4), 551-553.
Archin, N.M., et al. (2012). Vorinostat disrupts HIV-1 latency. Nature, 487(7408), 482-485.
Bassett, C.A.L., Mitchell, S.N., & Gaston, S.R. (1982). Pulsing electromagnetic field treatment in ununited fractures. JAMA, 247(5), 623-628.
Baati, T., et al. (2021). 528 Hz sound wave represses oxidative stress in rat brain. Journal of Biomedical Science, 28(1), 2.
Belluzzi, A., et al. (1996). Omega-3 in Crohn's disease. New England Journal of Medicine, 334(24), 1557-1560.
Bhattacharya, S., et al. (2017). Deuterium-depleted water in non-small cell lung cancer. PLOS ONE, 12(10), e0187010.
Birkmayer, J.G., et al. (1993). NADH supplementation in Parkinson's disease. Acta Neurologica Scandinavica, 87(Suppl 146), 32-35.
Chevalier, G., et al. (2012). Earthing: health implications of body-to-Earth electron transfer. Journal of Environmental and Public Health, 291541.
Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis in diabetic nephropathy. Lasers in Medical Science, 34(6), 1133-1142.
Clark, L.C., et al. (1996). Selenium supplementation for cancer prevention. JAMA, 276(24), 1957-1963.
Duggan, C., et al. (2004). Glutamine supplementation in catabolic patients. Annual Review of Nutrition, 22, 457-476.
Ebringer, A., Rashid, T., & Wilson, C. (2006). Ankylosing spondylitis, HLA-B27, and Klebsiella. Autoimmunity Reviews, 6(1), 9-17.
Eisenberg, T., et al. (2009). Spermidine induces autophagy and promotes longevity. Nature Cell Biology, 11(11), 1305-1314.
Fallahi, P., et al. (2016). Vitiligo and Hashimoto's thyroiditis. Reviews in Endocrine and Metabolic Disorders, 17(4), 515-521.
Garland, C.F., et al. (2006). Vitamin D and colorectal cancer. American Journal of Public Health, 96(2), 252-261.
Garneata, L., et al. (2016). Ketoanalogues + very-low-protein diet in CKD. Nephrology Dialysis Transplantation, 31(6), 968-975.
George, J., et al. (2019). NAC in idiopathic pulmonary fibrosis. European Respiratory Review, 28(152), 190040.
Griffin, X.L., et al. (2011). Electromagnetic field stimulation for fractures — Cochrane Review. Cochrane Database, CD008471.
Griffith, R.S., et al. (1987). Lysine therapy in herpes simplex infection. Dermatologica, 156(5), 257-267.
Hadanny, A., et al. (2020). HBOT improves post-stroke patients. Aging (Albany NY), 12(11), 10853.
Hamblin, M.R. (2017). Anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
Iaccarino, H.F., et al. (2016). Gamma frequency entrainment attenuates amyloid. Nature, 540(7632), 230-235.
Iepsen, E.W., et al. (2015). GLP-1 treatment reduces bone resorption. Journal of Clinical Endocrinology, 100(2), 473-479.
Jayawardena, R., et al. (2012). Zinc supplementation in type 2 diabetes. BMC Endocrine Disorders, 12, 26.
Katzenschlager, R., et al. (2004). Mucuna pruriens in Parkinson's disease. Neurology, 62(10), 1835-1837.
Klucken, J., et al. (2004). HSP70 inhibits alpha-synuclein aggregation. Journal of Biological Chemistry, 279(23), 25497-25502.
König, D., et al. (2018). Collagen peptides improve bone mineral density. Nutrients, 10(1), 97.
Larmo, P.S., et al. (2014). Sea buckthorn oil attenuates vaginal atrophy. Maturitas, 79(3), 316-321.
Leung, A.M., & Braverman, L.E. (2014). Iodine-induced thyroid dysfunction. Current Opinion in Endocrinology, 21(5), 378-384.
Lv, J., et al. (2011). Astragalus membranaceus modulates podocyte injury. Kidney Blood Pressure Research, 34(4), 235-242.
Martincorena, I., et al. (2015). Somatic mutations in normal skin. Science, 348(6237), 880-886.
Pittler, M.H., & Ernst, E. (1998). Horse chestnut seed extract for chronic venous insufficiency. Archives of Dermatology, 134(11), 1356-1360.
Pollack, G.H. (2013). The Fourth Phase of Water. Ebner & Sons Publishers.
Rodriguez-Moran, M., & Guerrero-Romero, F. (2003). Oral magnesium supplementation improves insulin sensitivity. Diabetes Care, 26(4), 1147-1152.
Sathavarat, K., et al. (2024). Ketogenic diet in type 2 diabetes: systematic review. Nutrition Reviews, 82(1), 1-12.
Schurgers, L.J., et al. (2007). Menaquinone-7 vs. synthetic vitamin K1. Blood, 109(8), 3279-3283.
Seyfried, T.N., et al. (2014). Metabolic management of cancer. Nutrition & Metabolism, 11(1), 40.
Stepien, M., et al. (2017). Copper/zinc biomarkers and colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention, 26(12), 1799-1807.
Steffan, J.S., et al. (2001). HDAC inhibitors arrest polyglutamine neurodegeneration. Nature, 413(6857), 739-743.
Thaut, M.H., et al. (1996). Rhythmic auditory stimulation in Parkinson's gait. Movement Disorders, 11(2), 193-200.
Toulis, K.A., et al. (2010). Selenium supplementation in Hashimoto's thyroiditis. Thyroid, 20(10), 1163-1173.
Wang, X., et al. (2018). Photobiomodulation in pulmonary fibrosis. Lasers in Medical Science, 33(8), 1713-1721.
Wang, X., et al. (2020). Photobiomodulation attenuates renal injury. Lasers in Surgery and Medicine, 52(8), 789-798.
Wichman, J., et al. (2016). Selenium supplementation in Hashimoto's — systematic review. European Thyroid Journal, 5(4), 253-261.
Yaghoobi, N., et al. (2011). Zinc sulfate for vitiligo. Journal of Drugs in Dermatology, 10(7), 729-733.
Yang, M., & Brackenbury, W.J. (2013). Membrane potential and cancer progression. Frontiers in Physiology, 4, 185.
Yin, J., et al. (2008). Berberine for cholesterol and glucose. Nature Medicine, 8(12), 1421-1427.